Hoth Therapeutics announces final results from 14-day Phase 1b trial of BioLexa

Hoth Therapeutics announced that it has completed its analysis of the data from its Phase 1b clinical trial of BioLexa as a therapeutic for atopic dermatitis. Patients were randomized into 3 blinded treatments of the BioLexa lotion, gentamicin lotion, or placebo over a 14-day treatment period. Patients eligible to be enrolled in this trial had mild to moderate disease. Treatment with BioLexa over the 14-day treatment period led to a 35% improvement in SCORAD measurement and a 60% improvement in EASI measurement of atopic skin disease, whereas gentamicin lotion and placebo had no effect. In addition, patient-reported DLQI found that BioLexa use led to a 46% improvement in patient quality of life, whereas gentamicin lotion and placebo had no effect. Finally, when asked about their general impression of care since starting the study, 78% of patients reported that their overall health had improved since starting BioLexa, as compared to 22% stating that there was no change in their health, or their health was worse.